Kennedy Capital Management’s Anika Therapeutics ANIK Stock Holding History

Kennedy Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,261	Closed	-$460K	–	730
2018 Q1	$460K	Buy	+9,261	New	+$523K	0.01%	700
2017 Q4	–	Sell	-23,825	Closed	-$1.38M	–	743
2017 Q3	$1.38M	Sell	23,825 -13,047	-35%	-$682K	0.02%	641
2017 Q2	$1.82M	Buy	+36,872	New	+$1.7M	0.03%	600
2016 Q2	–	Sell	-9,049	Closed	-$405K	–	706
2016 Q1	$405K	Hold	9,049	–	–	0.01%	702
2015 Q4	$345K	Sell	9,049 -9,441	-51%	-$361K	0.01%	710
2015 Q3	$589K	Sell	18,490 -5,009	-21%	-$175K	0.01%	683
2015 Q2	$776K	Buy	23,499 +2,145	+10%	+$76.5K	0.01%	686
2015 Q1	$879K	Buy	21,354 +11,157	+109%	+$451K	0.02%	668
2014 Q4	$415K	Buy	+10,197	New	+$399K	0.01%	717
2014 Q1	–	Sell	-18,211	Closed	-$695K	–	740
2013 Q4	$695K	Buy	18,211 +3,211	+21%	+$99.1K	0.01%	676
2013 Q3	$358K	Buy	+15,000	New	+$337K	0.01%	723

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Kennedy Capital Management's ANIK Position: Q2 2018 in Review

Kennedy Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2018, closing a stake of 9,261 shares — an estimated $460K sold.

Kennedy Capital Management first reported a position in ANIK in Q3 2013 and held it in 11 quarters. The position peaked at $1.82M in Q2 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q2 2018.

Kennedy Capital Management reported no remaining Anika Therapeutics position as of Q2 2018 after selling out during the quarter.
Kennedy Capital Management sold 9,261 Anika Therapeutics shares in Q2 2018, an estimated $460K.
Kennedy Capital Management first reported a position in Anika Therapeutics in Q3 2013 and held it in 11 quarters.
Kennedy Capital Management's Anika Therapeutics position peaked at $1.82M in Q2 2017.
170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2018.

Based on Kennedy Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.